Efficacy of ribavirin against malignant glioma cell lines

Akiyoshi Ogino, Emiko Sano, Yushi Ochiai, Shun Yamamuro, Shinya Tashiro, Kazunari Yachi, Takashi Ohta, Takao Fukushima, Yutaka Okamoto, Kouhei Tsumoto, Takuya Ueda, Atsuo Yoshino, Yoichi Katayama

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Ribavirin (1-β-D-ribofuranosy-1,2,4-triazole- 3-carboxamide) has been widely administered as an antiviral agent against RNA and DNA viruses. Ribavirin, in combination with interferon, has predominantly been applied in the treatment of the hepatitis C virus infection and its potential antitumor efficacy has recently become a point of interest. The aim of the present study was to evaluate the effect of ribavirin on the growth of malignant glioma cells, to identify novel predictive genes in malignant glioma cells (by analyzing gene expression profiles) and to assess the influence of ribavirin on the cell cycle of malignant glioma cells. The present study evaluated the antitumor efficacy of ribavirin against various malignant glioma cell lines (A-172, AM-38, T98G, U-87MG, U-138MG, U-251MG and YH-13). After culturing the cells in ribavirin-containing culture medium (final concentration, 0-1,000 μM) for 72 h, the viable proliferated cells were harvested and counted. The half maximal inhibitory concentration of ribavirin, with regard to the growth of the malignant glioma cell lines, was determined from the concentration of ribavirin required for 50% growth inhibition in comparison to the untreated control cells. Furthermore, the current study identified the genes in which the gene expression levels correlated with the ribavirin sensitivity of the malignant glioma cells lines, using a high-density oligonucleotide array. Finally, cell cycle analysis was performed on the U-87MG cell line. It was identified that ribavirin inhibited the growth of all of the malignant glioma cell lines in a dose-dependent manner, although the ribavirin sensitivity varied between each cell line. Of the extracted genes, PDGFRA demonstrated the strongest positive correlation between gene expression level and ribavirin sensitivity. Cell cycle analysis of the U-87MG cell line demonstrated that ribavirin treatment induces G0/G1 arrest and thus may be an effective agent for inhibiting malignant glioma cell growth. Therefore, the results of the current study indicate that ribavirin may have potential as a therapeutic agent in the treatment of malignant gliomas.

Original languageEnglish
Pages (from-to)2469-2474
Number of pages6
JournalOncology Letters
Volume8
Issue number6
DOIs
Publication statusPublished - 2014 Dec 1
Externally publishedYes

Fingerprint

Ribavirin
Glioma
Cell Line
Growth
Cell Cycle
Genes
Gene Expression
DNA Viruses
RNA Viruses
Virus Diseases
Oligonucleotide Array Sequence Analysis
Transcriptome
Hepacivirus
Interferons
Antiviral Agents
Culture Media

Keywords

  • Malignant glioma
  • Ribavirin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ogino, A., Sano, E., Ochiai, Y., Yamamuro, S., Tashiro, S., Yachi, K., ... Katayama, Y. (2014). Efficacy of ribavirin against malignant glioma cell lines. Oncology Letters, 8(6), 2469-2474. https://doi.org/10.3892/ol.2014.2569

Efficacy of ribavirin against malignant glioma cell lines. / Ogino, Akiyoshi; Sano, Emiko; Ochiai, Yushi; Yamamuro, Shun; Tashiro, Shinya; Yachi, Kazunari; Ohta, Takashi; Fukushima, Takao; Okamoto, Yutaka; Tsumoto, Kouhei; Ueda, Takuya; Yoshino, Atsuo; Katayama, Yoichi.

In: Oncology Letters, Vol. 8, No. 6, 01.12.2014, p. 2469-2474.

Research output: Contribution to journalArticle

Ogino, A, Sano, E, Ochiai, Y, Yamamuro, S, Tashiro, S, Yachi, K, Ohta, T, Fukushima, T, Okamoto, Y, Tsumoto, K, Ueda, T, Yoshino, A & Katayama, Y 2014, 'Efficacy of ribavirin against malignant glioma cell lines', Oncology Letters, vol. 8, no. 6, pp. 2469-2474. https://doi.org/10.3892/ol.2014.2569
Ogino A, Sano E, Ochiai Y, Yamamuro S, Tashiro S, Yachi K et al. Efficacy of ribavirin against malignant glioma cell lines. Oncology Letters. 2014 Dec 1;8(6):2469-2474. https://doi.org/10.3892/ol.2014.2569
Ogino, Akiyoshi ; Sano, Emiko ; Ochiai, Yushi ; Yamamuro, Shun ; Tashiro, Shinya ; Yachi, Kazunari ; Ohta, Takashi ; Fukushima, Takao ; Okamoto, Yutaka ; Tsumoto, Kouhei ; Ueda, Takuya ; Yoshino, Atsuo ; Katayama, Yoichi. / Efficacy of ribavirin against malignant glioma cell lines. In: Oncology Letters. 2014 ; Vol. 8, No. 6. pp. 2469-2474.
@article{61b365ae50764ecb9113e433743b2abb,
title = "Efficacy of ribavirin against malignant glioma cell lines",
abstract = "Ribavirin (1-β-D-ribofuranosy-1,2,4-triazole- 3-carboxamide) has been widely administered as an antiviral agent against RNA and DNA viruses. Ribavirin, in combination with interferon, has predominantly been applied in the treatment of the hepatitis C virus infection and its potential antitumor efficacy has recently become a point of interest. The aim of the present study was to evaluate the effect of ribavirin on the growth of malignant glioma cells, to identify novel predictive genes in malignant glioma cells (by analyzing gene expression profiles) and to assess the influence of ribavirin on the cell cycle of malignant glioma cells. The present study evaluated the antitumor efficacy of ribavirin against various malignant glioma cell lines (A-172, AM-38, T98G, U-87MG, U-138MG, U-251MG and YH-13). After culturing the cells in ribavirin-containing culture medium (final concentration, 0-1,000 μM) for 72 h, the viable proliferated cells were harvested and counted. The half maximal inhibitory concentration of ribavirin, with regard to the growth of the malignant glioma cell lines, was determined from the concentration of ribavirin required for 50{\%} growth inhibition in comparison to the untreated control cells. Furthermore, the current study identified the genes in which the gene expression levels correlated with the ribavirin sensitivity of the malignant glioma cells lines, using a high-density oligonucleotide array. Finally, cell cycle analysis was performed on the U-87MG cell line. It was identified that ribavirin inhibited the growth of all of the malignant glioma cell lines in a dose-dependent manner, although the ribavirin sensitivity varied between each cell line. Of the extracted genes, PDGFRA demonstrated the strongest positive correlation between gene expression level and ribavirin sensitivity. Cell cycle analysis of the U-87MG cell line demonstrated that ribavirin treatment induces G0/G1 arrest and thus may be an effective agent for inhibiting malignant glioma cell growth. Therefore, the results of the current study indicate that ribavirin may have potential as a therapeutic agent in the treatment of malignant gliomas.",
keywords = "Malignant glioma, Ribavirin",
author = "Akiyoshi Ogino and Emiko Sano and Yushi Ochiai and Shun Yamamuro and Shinya Tashiro and Kazunari Yachi and Takashi Ohta and Takao Fukushima and Yutaka Okamoto and Kouhei Tsumoto and Takuya Ueda and Atsuo Yoshino and Yoichi Katayama",
year = "2014",
month = "12",
day = "1",
doi = "10.3892/ol.2014.2569",
language = "English",
volume = "8",
pages = "2469--2474",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Efficacy of ribavirin against malignant glioma cell lines

AU - Ogino, Akiyoshi

AU - Sano, Emiko

AU - Ochiai, Yushi

AU - Yamamuro, Shun

AU - Tashiro, Shinya

AU - Yachi, Kazunari

AU - Ohta, Takashi

AU - Fukushima, Takao

AU - Okamoto, Yutaka

AU - Tsumoto, Kouhei

AU - Ueda, Takuya

AU - Yoshino, Atsuo

AU - Katayama, Yoichi

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Ribavirin (1-β-D-ribofuranosy-1,2,4-triazole- 3-carboxamide) has been widely administered as an antiviral agent against RNA and DNA viruses. Ribavirin, in combination with interferon, has predominantly been applied in the treatment of the hepatitis C virus infection and its potential antitumor efficacy has recently become a point of interest. The aim of the present study was to evaluate the effect of ribavirin on the growth of malignant glioma cells, to identify novel predictive genes in malignant glioma cells (by analyzing gene expression profiles) and to assess the influence of ribavirin on the cell cycle of malignant glioma cells. The present study evaluated the antitumor efficacy of ribavirin against various malignant glioma cell lines (A-172, AM-38, T98G, U-87MG, U-138MG, U-251MG and YH-13). After culturing the cells in ribavirin-containing culture medium (final concentration, 0-1,000 μM) for 72 h, the viable proliferated cells were harvested and counted. The half maximal inhibitory concentration of ribavirin, with regard to the growth of the malignant glioma cell lines, was determined from the concentration of ribavirin required for 50% growth inhibition in comparison to the untreated control cells. Furthermore, the current study identified the genes in which the gene expression levels correlated with the ribavirin sensitivity of the malignant glioma cells lines, using a high-density oligonucleotide array. Finally, cell cycle analysis was performed on the U-87MG cell line. It was identified that ribavirin inhibited the growth of all of the malignant glioma cell lines in a dose-dependent manner, although the ribavirin sensitivity varied between each cell line. Of the extracted genes, PDGFRA demonstrated the strongest positive correlation between gene expression level and ribavirin sensitivity. Cell cycle analysis of the U-87MG cell line demonstrated that ribavirin treatment induces G0/G1 arrest and thus may be an effective agent for inhibiting malignant glioma cell growth. Therefore, the results of the current study indicate that ribavirin may have potential as a therapeutic agent in the treatment of malignant gliomas.

AB - Ribavirin (1-β-D-ribofuranosy-1,2,4-triazole- 3-carboxamide) has been widely administered as an antiviral agent against RNA and DNA viruses. Ribavirin, in combination with interferon, has predominantly been applied in the treatment of the hepatitis C virus infection and its potential antitumor efficacy has recently become a point of interest. The aim of the present study was to evaluate the effect of ribavirin on the growth of malignant glioma cells, to identify novel predictive genes in malignant glioma cells (by analyzing gene expression profiles) and to assess the influence of ribavirin on the cell cycle of malignant glioma cells. The present study evaluated the antitumor efficacy of ribavirin against various malignant glioma cell lines (A-172, AM-38, T98G, U-87MG, U-138MG, U-251MG and YH-13). After culturing the cells in ribavirin-containing culture medium (final concentration, 0-1,000 μM) for 72 h, the viable proliferated cells were harvested and counted. The half maximal inhibitory concentration of ribavirin, with regard to the growth of the malignant glioma cell lines, was determined from the concentration of ribavirin required for 50% growth inhibition in comparison to the untreated control cells. Furthermore, the current study identified the genes in which the gene expression levels correlated with the ribavirin sensitivity of the malignant glioma cells lines, using a high-density oligonucleotide array. Finally, cell cycle analysis was performed on the U-87MG cell line. It was identified that ribavirin inhibited the growth of all of the malignant glioma cell lines in a dose-dependent manner, although the ribavirin sensitivity varied between each cell line. Of the extracted genes, PDGFRA demonstrated the strongest positive correlation between gene expression level and ribavirin sensitivity. Cell cycle analysis of the U-87MG cell line demonstrated that ribavirin treatment induces G0/G1 arrest and thus may be an effective agent for inhibiting malignant glioma cell growth. Therefore, the results of the current study indicate that ribavirin may have potential as a therapeutic agent in the treatment of malignant gliomas.

KW - Malignant glioma

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=84908043676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908043676&partnerID=8YFLogxK

U2 - 10.3892/ol.2014.2569

DO - 10.3892/ol.2014.2569

M3 - Article

VL - 8

SP - 2469

EP - 2474

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 6

ER -